Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT04451330 Completed - Acne Vulgaris Clinical Trials

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

DUAL
Start date: July 29, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study was to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV.

NCT ID: NCT04433143 Enrolling by invitation - Acne Vulgaris Clinical Trials

Evaluate the Efficacy and Safety of Intense Pulsed Light Filters Combined With Oral Medication in the Treatment of Acne

Start date: May 15, 2020
Phase: N/A
Study type: Interventional

1. Acne is a chronic inflammatory disease involving the hair follicles and sebaceous glands, characterized by acne, papules, pustules, nodules, and cysts. Acne often occurs in sebum overflow areas such as the face, chest, back and so on. It is a common skin lesion, which not only affects physical health, but also brings psychological disorders and psychosocial problems to patients. At present, the common treatment methods of acne include health education, topical drugs, oral drugs and medical cosmetic treatment. 2. Intense pulsed light has been widely accepted as a non-invasive and non-serious treatment for acne. The M22 strong light and laser system Acne filter has a wavelength of 400-600/800-1200nm. 3. Although there are many treatments for acne, the slow response and easy recurrence of acne are still common problems that trouble doctors and patients. We clinically use drugs combined with intense pulsed light treatment, and the efficacy of the patients is fair, but currently lack of clinical research data support. This study intends to evaluate the effectiveness of different methods in the treatment of moderate and severe acne by evaluating different bands of intense pulsed light combined with drugs, and to observe whether the treatment with oral tetracycline antibiotics combined with intense pulsed light is safe.

NCT ID: NCT04367584 Completed - Acne Vulgaris Clinical Trials

Comparison of Malassezia Spp Proportions in Inflammatory and Non Inflammatory Facial Acne Vulgaris Lesions

Start date: October 1, 2018
Phase:
Study type: Observational

Acne vulgaris (AV) is a common inflammatory condition involving pilosebaceous unit. The pathogenesis of acne is multifactorial and skin microbiome is considered to be one of the key factors that aggravate inflammation. Malassezia spp is normal flora on the skin and several studies have reported its corelation with inflammatory AV lesion. Malassezia have higher lipase activity compared to Propionibacterium acnes which triggers an increase in free fatty acid and glycerol, the chemotactic factors towards neutrophils and inducing inflammation in AV. Malassezia folliculitis (MF) is sometimes confused with and may present together with AV. Pruritus usually presents in MF but some studies also reported itching as common symptom in AV. The objectives of this study were to identify the presence and the distribution of Malassezia spp. in facial AV lesions, to compare the distribution of Malassezia spp. between inflammatory and non-inflammatory lesions and to identify the association between Malassezia spp in acne lesions and pruritus symptom.

NCT ID: NCT04329403 Withdrawn - Acne Vulgaris Clinical Trials

Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%

Start date: July 2020
Phase: Phase 3
Study type: Interventional

To evaluate the therapeutic equivalence of topical Adapalene Gel, 0.1 % and Differin®(Adapalene) Gel, 0.1 % in the treatment of acne vulgaris and to demonstrate the superiority of the efficacy of the test and reference products over the placebo.

NCT ID: NCT04321070 Completed - Acne Vulgaris Clinical Trials

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Start date: September 9, 2019
Phase: Phase 1
Study type: Interventional

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

NCT ID: NCT04301063 Completed - Acne Vulgaris Clinical Trials

Assess the Effects and the Tolerance of Cosmetic Product in the Follow-up Phase of Facial Acne for 1 Year

Start date: February 4, 2019
Phase:
Study type: Observational

Acne is a chronic inflammatory disease of the pilo-sebaceous unit in the skin. Indeed, your skin is covered with tiny holes called hair follicles, or pores. These pores contain sebaceous glands (also called oil glands) that make sebum, an oil that moistens your hair and skin. Most of the time, the glands make the right amount of sebum and the pores are fine. But sometimes a pore gets clogged up with too much sebum, dead skin cells, and germs called bacteria. This can cause acne. Pierre Fabre Laboratories have developed a cosmetic care product, a cream which is commercialized since September 2019. This leave-on skin care product is adapted for acne-prone skin. In this study, we are interested in the effects of this care product in facial acne evolution for 12 months (quality of life, acne severity, number of acne flares). Also, we are interested in the subject's satisfaction regarding the use of this care product. This study will also enable to know if the product is well tolerated in such application circumstances. This clinical study will be carried out in 54 subjects (female or male), aged between 12 and 35 years, in about 10 centers in different European countries. The maximal duration of the study for a subject will be 1 year. If you give your consent to take part in this study, you will receive a cosmetic care product, also called study product, that you will apply on your face twice a day (morning and evening) for the whole duration of the study. What makes this study original is the use of a smartphone application to help you to comply with the study procedures and to help the investigator to follow you.

NCT ID: NCT04300010 Completed - Acne Clinical Trials

Blue Light Therapy of C. Acnes

Start date: October 5, 2020
Phase: Phase 4
Study type: Interventional

This proposal aims to investigate a novel light-based treatment to reduce morbidity in shoulder surgical patients. This has potential to improve outcomes and reduce health care utilization associated with infectious complications of shoulder arthroplasty. Participants will be healthy male volunteers at least 18 years of age. They will be on study for approximately 2 days.

NCT ID: NCT04254601 Completed - Skin Diseases Clinical Trials

Laser Therapy Versus Narrow Band Ultraviolet B for the Treatment of Acne Vulgaris

LLLT-NBUB
Start date: April 1, 2018
Phase: N/A
Study type: Interventional

Forty-five participants with facial AV were assigned randomly to three groups of fifteen subjects each. Each group received various therapies. Group A (Study group A) had received both NBUB and akne-Mycin; Group B( study group B) had received Red LLLT and akne-Mycin and group C (Control group) received only akne-Mycin cream. All 45 participants are tested at the initial treatments, after 4 weeks and after 8 weeks by the acne count, the intensity scale and the photographic test.

NCT ID: NCT04224597 Not yet recruiting - Acne Vulgaris Clinical Trials

Evaluation of the Presence of Enthesitis in Patients With Acne Vulgaris

Start date: February 1, 2020
Phase:
Study type: Observational

Acne vulgaris is an inflammatory disease of the pilosebaceous unit, affecting about 85% of the young population. In the studies p. acne is a potent stimulator of the release of IFN-gamma (IFN-)) and IL-17 from CD4 + T cells, and the presence of IL-17 + cells in the perifollicular infiltrate has been shown in biopsies of inflammatory acne lesions. Therefore, acne is thought to be a Th17-related disease (1). This study was aimed to evaluate the presence of enthesitis in patients with acne vulgaris.

NCT ID: NCT04216160 Completed - Acne Vulgaris Clinical Trials

Skin Acceptance and Efficacy Assessment of a Topical Product in Acne Treatment When Compared to a Placebo.

Start date: May 5, 2019
Phase: N/A
Study type: Interventional

In this study the topical use of cream with live probiotic bacteria was evaluated for its efficacy in reducing acne symptoms and its effect on the skin microbiota on patients with acne vulgaris. Patients with mild to moderate acne used the probiotic cream for 8 weeks and clinical evaluation and microbiological sampling was done at start, 2, 4, 8 and 12 weeks (after 4 weeks without use of the product). Next-Generation Sequencing is used to analyze the skin microbiota of the patients.